dataesr/scientific-paragraphs-categorization huggingface dataset:
Patients with relapsed/refractory multiple myeloma (RRMM) typically report poor health-related quality of life (HRQoL), which deteriorates as they progress through multiple lines of therapy. This study provides HRQoL data in patients with RRMM who received teclistamab in MajesTEC-1, including improvements in pain, global health status, and emotional functioning. These results support teclistamab as a promising treatment option in this population. Introduction: Patients with relapsed or refractory multiple myeloma (RRMM) report significantly lower HRQoL compared with patients with newly diagnosed MM and experience further deterioration in HRQoL with each relapse and subsequent treatment. Therefore, consideration of the impact of treatment on HRQoL in addition to clinical outcomes is vital. Patients and Methods: In the phase I/II MajesTEC-1 (NCT03145181, NCT04557098) study, patients with RRMM who received teclistamab, an off-the-shelf, T-cell redirecting BCMA × CD3 bispecific antibody, had deep and durable responses with manageable safety.
Study Design and Patients The study design and methods of the MajesTEC-1 study have been published. 14  Briefly, this was an open-label, multicenter, phase I (NCT03145181) and phase II (NCT04557098) study in patients with RRMM. In phase II, patients received the RP2D of teclistamab (weekly subcutaneous dose of 1. 5 mg/kg preceded by stepup doses of 0. 06 and 0. 3 mg/kg). Eligible patients were adults with a diagnosis of RRMM; progressive, measurable disease per International Myeloma Working Group (IMWG) criteria  18  ; and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients must have also received ≥3 prior lines of therapy, including a PI, an IMiD, and an anti-CD38 mAb. Patients who had received prior BCMA-targeted therapy were not eligible. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
Patient Characteristics and Compliance With PROs In total, 165 patients were treated with teclistamab at the RP2D in phase I and phase II; all 125 patients enrolled in phase II provided PRO data for analyses. Among all 165 patients, the median duration of treatment was 8. 5 months (range, 0. 2-24. 4). The median age was 64 years (range, 33-83), and 56% of patients were male ( Table  1  ). Patients had previously received a median of 5 prior lines of therapy (range, 2-14). Mean EORTC QLQ-C30 values at baseline reflected the poor overall GHS in this RRMM population, with the greatest impacts in role and physical functioning and symptoms of pain and fatigue ( Table  1  ). Compliance rates for all patients who provided PRO assessments (n = 125) were 83% at baseline for the EORTC QLQ-C30 and 77% for the EQ-5D-5L and were similar through cycle 8 ( ≥77%).
Acknowledgments The authors wish to thank all patients who volunteered to participate in this study, their families and caregivers, the staff members at the study sites who supported this study, the data and safety monitoring committee, and all staff involved in data collection and analysis. Editorial and medical writing support was provided by  Rachael Smith, PhD , of  Eloquent Scientific Solutions  , and funded by  Janssen Global Services, LLC. The MajesTEC-1 study was funded by  Janssen Research & Development, LLC. Medical writing support was provided by  Rachael Smith, PhD , of  Eloquent Scientific Solutions  , and funded by  Janssen Global Services, LLC.
Acknowledgments This work was supported by the  Chaire Industrielle Trace   ANR-17-CHIN-0004-01 co- funded  865  by the  ANR French  national research agency,  TotalEnergies-Raffinage Chimie ,  SUEZ , and  THALES ALENIA SPACE. We would also like to thank the  SUEZ  site staff for their assistance in the measurement campaigns. We also acknowledge  IFP Energies nouvelles-Géoscience, France  for participating to some of the campaigns.
Discussions and interpretations In the previous sections, the results of the interlaboratory study for two different materials, silica and lactose, were presented. The two materials were analysed via inverse gas chromatography by different organizations under the given conditions using different IGC equipment. The specific retention volume V G as well as the dispersive surface energy component γ d s , and the ISP values of certain solvents were calculated from the obtained measurement data t N. A detailed overview of all results can be found in the supplementary information (Table  2 -7 for silica and in Table  9 -14 for lactose). The discussion and interpretations focus on two key aspects: Firstly, how significant are observed differences for the key parameters γ d s and ISP and secondly, what could be potential causes for the observed deviations? Finally, there are additional thoughts and suggestions for future improvements of IGC measurements.
Conclusion This is the first time that an interlaboratory study has been conducted on two exemplary materials, silica and lactose, which were analysed by eight different organizations, from academia as well as industry, to investigate the reproducibility and robustness of IGC results. Different types of inverse gas chromatographs have been used, which differ mainly in their dosing system, either syringe-or valve-based. The measurements were conducted according to a protocol that was jointly defined prior to the interlaboratory study and the raw data is collected and evaluated using identical mathematical operations according to standard IGC theories. The results of the specific retention volume V G , the dispersive component of surface energy γ d s as well as the specific interaction parameters ISP for certain probe molecules are compared to examine the general reproducibility of the IGC.
Acknowledgments The authors thank all participating organizations and their numerous, engaged members to support this work, namely and in alphabetic order: Adscientis,  BASF ,  F. Hoffmann -La Roche ,  Helmholtz Institute Freiberg for Resource Technology, University Leipzig ,  Madirel Laboratories, Porcher Industries, Poznan University. A special thanks from all participating organizations to  Eric Brendlé , who initiated and greatly supported this initiative and always believes in science. It has not been easy, but we hope that our study further improves the IGC method!.
Protein interactomics and pathways of BCL11b To characterize the protein interactants and pathways triggered by BCL11b, we used HEK cells overexpressing Flag-BCL11b. After proteins pull-down using anti-flag antibodies, we performed quantitative LC-MS/MS. After statistical analysis, we identified 629 BCL11b protein partners (supplementary method file S1 and supplementary dataset S1). Among the interacting proteins, we can confirm the previously described interactions between BCL11b and the P-TEFb complex (including CDK9 and CycT1)  (Cherrier et al. , 2013) , HDACs  (Marban et al. , 2007) , HMGA1  (Eilebrecht et al. , 2014) , HP1 proteins  (Rohr et al. , 2003) , KU proteins  (Shadrina et al. , 2020) , and DCAF1  (Forouzanfar et al. , 2019)  as a validation of our experimental approach (Figure  1A ).
We analyzed the results by two approaches, as the following: First, number of CLIP reads mapped to a gene feature were counted and the genes that are enriched over the control samples were selected (see method in Suppl. file S1), which lead to a dataset of 740 different genes (figure 2, 3A, S1-S5 and Suppl. data S3). We found that about 96% of the BCL11b-bound RNAs are mapped to protein-coding genes (Table  S1 ). BCL11b tends to bind to transcripts of long genes. Among the genes that have high numbers of CLIP reads, we found that about 20% are over 100kb in length, whereas the average length of these genes is 61kb, which is two-fold the genomics length (~30kb). The longest gene is Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 1 (AGAP1, NCBI GeneID: preprint (which was not certified by peer review) is the author/funder.
One can speculate that depletion of BCL11b could lead to isoform switching and translation of wrong isoform of the protein (misfolded or short) but this needs to be formally demonstrated. Although the exact role of BCL11b in diseases deserve to be studied by future research, our results offer potential genome-wide RNA and proteins datasets, which will help future efforts to understand the molecular basis of cancer and neurodegenerative diseases. These proteins were previously shown to interact with BCL11b and we can detect them by IP-MS method. The gene names of BCL11b-bound ncRNAs are written in blue. B) GO terms of BCL11b-interacting proteins (BIPs), X-axis show percent of BIPs to the total number of proteins identified in this category. C) Four representative GO terms with the list of proteins that are detected to bind to BCL11b.
Funding: This work was supported by the  French agency  for research on AIDS and viral hepatitis (ANRS); SIDACTION; the  European Union 's  Horizon 2020 research and innovation programme  under grant agreement No  691119-EU4HIVCURE-H2020-MSCA-RISE-2015 ; The  Belgian Fund for Scientific Research (FRS-FNRS, Belgium) , the " Fondation Roi Baudouin ", the  Walloon Region (Fonds de Maturation) and the university of Brussels (Action de Recherche Concertée (ARC)  grant). The laboratory of CVL is part of the  ULB-Cancer Research Centre (U-CRC ). AAA is a fellow of the  Wallonie-Bruxelles International program  and of the  Marie Skłodowska Curie COFUND action. HS is a fellow of  ANRS. MDR is a fellow of  University of Strasbourg. CVL is Directeur de Recherches of the F. R. S-FNRS, Belgium. preprint (which was not certified by peer review) is the author/funder.
Acknowledgments Authors are grateful to  Daniel Weimer  from  Virginia Tech ,  Urs Ganse  and  Yann Kempf  from  University of Helsinki ,  San Lu  from  USTC , and  Chuanfei Dong  from  Boston University  for helpful discussions. This work was supported by the  National Key R&D program of China  No. 2021YFA0718600 ,  NNFSC  grants  42150105 ,  42188101 , and  42274210 , and the  Specialized Research Fund for State Key Laboratories of China. The computations are performed by  Numerical Forecast Modeling R&D  and  VR System of State Key Laboratory of Space Weather , and  HPC of Chinese Meridian Project  using the RHybrid code distributed under the open source GPL v3 license by the  Finnish Meteorological Institute  (github. com /fmihpc/rhybrid).
Acknowledgements This study emerged during the  PAGES-supported Global Paleofire Working Group 2 workshop "Fire history baselines by biome " held in September 2016 at  Château de la Tour, Beguey (Bordeaux, France ) led by A. -L. D. and  Tim Brücher. PAGES ,  Past Global Changes , is funded by the  Swiss Academy of Sciences  and the  Chinese Academy of Sciences  and supported in kind by the  University of Bern, Switzerland. Financial support was provided by the  U. S. National Science Foundation  award numbers  1916565 ,  EAR-2011439 , and  EAR-2012123. Additional support was provided by the  Utah Department of Natural Resources Watershed Restoration Initiative. SSS was supported by  Brigham Young University Graduate Studies. MS was supported by  National Science Centre, Poland  (grant no. 2018/31/B/ST10/02498 ).
Experimental procedure The hammer impact test consists of three stages: (a) structure fabrication, (b) sampling measurement, and (c) data processing and analysis. After the constrained damping lining structures were fabricated and cured, the single point hammering vibration tests were conducted  (Li et al. , 2022). The measurement system is shown in Fig. 3. In order to mitigate the ground contact influence on the test results, two wooden strips were placed at both structure ends as buffer cushions  (Yan et al. , 2023). The impactor was used to strike the center point of the upper lining structure surface to simulate vibration transmitted from the surrounding rocks to lining. Three accelerometers were set equidistantly on the bottom surface central axis. Thus, the signals of the impactor and accelerometers could be collected by a dynamic data acquisition system, and then they were transmitted to the personal computer (PC).
5 mm/min. The displacement and force on the top of the model were monitored. The numerical calculation results of the stress-strain curve of the RSC under the uniaxial compression condition are shown in Fig. 9. It can be seen from Fig. 9  that the numerical data of the stressstrain curve match well with the experimental results, which can accurately reflect the mechanical properties of the RSC. Meanwhile, the comparison of the RSC failure morphology between the numerical calculation and the experiment is shown in Fig. 10. The failure morphology of the sample in the numerical results is almost the same as the experimental one. The samples in these two different methods are mainly subjected to a shear failure of about 45. Therefore, the parameters used in the aseismic analysis model for the RSC as damping layer are considered as accurate and reliable.
Comparison between the numerical and experimental results For the hammer impact tests, 4 cases are set for different damping layer thickness and control group without constrained damping structure. The tunnel depths for these cases are both 300 m. The effective duration is selected as the aseismic performance indicator for the hammer impact tests for different damping layer thicknesses, while the maximum principal stress is selected as an indicator for numerical calculation in the aseismic analysis. Moreover, the maximum principal stress of the numerical results at four different monitoring points are selected (right and left spandrel, and right and left arch foot). All these data are normalized by  (Unlu and Gercek, 2003) : x 0 ¼ x À m s (8) where m and s are the mean and standard deviation of the original dataset, respectively.
Acknowledgments The work is supported by the  National Natural Science Foundation of China  (No. 52079133 ),  CRSRI Open Research Program  (Program SN:  CKWV2019746/KY ), the project of  Key Laboratory of Water Grid Project   and Regulation of Ministry of Water Resources  ( QTKS0034W23291 ), and the  Youth Innovation Promotion Association CAS. The authors want to thank all the members who give us lots of help and cooperation.
((((DAIR) OR (debridement)) OR (antibiotic)) OR (implant retention)) AND (infection)) AND (periprosthetic)) AND (hip)) AND (knee). Additional studies were searched among reference lists of selected papers and systematic reviews. Three independent reviewers (S. D. S. , B. B. , and A. L. ) separately conducted the study, and articles published from the inception of the databases until September 2022 have been included. The search was performed from August 2022 to September 2022.
Search results The literature search identified 695 total studies. No additional studies were found in the grey literature, and no unpublished studies were retrieved. Duplicated article removal resulted in the exclusion of 177 papers. Of the remaining 518 articles, 405 were removed as incompatible with the main aim of this review after the title and abstract evaluation. 113 full-text articles were then screened, leading to the elimination of 101 studies. In the latter exclusion process, the discarded articles were: articles reporting data from chronic or late-hematogenous PJIs (n ¼ 45), multicentre studies (n ¼ 14), and articles not specifying the type of PJI (n ¼ 17). Additionally, systematic reviews (n ¼ 14) and articles with no retrievable full text (n ¼ 11) were discarded. At the end of the selection process, a total of 12 articles were considered eligible for this study.
Acknowledgments Angela Lamarca  received funding from the  Spanish Society of Medical Oncology (SEOM) Fellowship Programme  (Return Fellowship) and  European Union 's  Horizon 2020 Research and Innovation Programme  (grant number  825510 , ESCALON). Medical writing assistance was provided by  Simon J. Slater, PhD , CMPP ( Envision Pharma Group, Philadelphia, PA, USA ), funded by  Incyte Corporation.
AOPs provide a framework for understanding the molecular and cellular events that lead to adverse outcomes (AOs) and can help to identify the mode of toxicity specific to critical properties of NMs  (Vietti et al. , 2016; Rolo et al. , 2022). By utilizing AOPs, researchers and regulators can overcome these challenges, ultimately leading to more accurate and comprehensive risk assessments  (Rolo et al. , 2022). To identify relevant studies, we conducted a literature review on mitochondrial toxicity induced by NMs (Fig. 2 ). A combination of keywords used in the Web of Science (WoS) database to search for relevant studies included [(nanoparticles or nanomaterials) AND (mitochondria) AND (in vitro)]. The search resulted in 1473 papers in total for studies published before 25/01/2023. After screening and applying different exclusion and inclusion criteria (see Fig.
1 and summarized mitochondrial toxicity endpoints and related methods/assays to measure them (Tab. 2). This includes endpoints such as mitochondrial complex inhibition, decrease in oxidative phosphorylation, MMP, ATP production as well as increase in mitochondrial ROS production and mitochondrial damage/dysfunction/disruption. These endpoints were then used to design a template, which was used to extract and consolidate data from the selected studies. We extracted data from the selected studies and analyzed it in two steps: 1) Analysis and evaluation of the evidence for NM-induced mitochondrial toxicity. This step summarized the studies reporting mitochondrial and cellular toxicity endpoints induced by NMs (such as titanium dioxide (TiO2), amorphous silica (SiO2), silver (Ag)), etc) in human cell types that are representative of a potential target organ/tissue (such as lung, liver, etc) or system (such as nervous).
3. 1 Evidence analysis of mitochondrial toxicity induced by different NMs Supplementary file 1 1  includes the list of selected studies, extracted raw data, and evaluation of these studies using a data quality scoring approach based on the GUIDEnano system. All studies are also marked by quality Q score. However, in order to address the gaps in the available data, we did not exclude studies based on their data quality but included all 78 studies in our data analyses. Indeed, only 25 out of the 78 studies had an acceptable Q value with very high, high or medium quality. In Supplementary file 2 2  , we organized the data from individual studies related to mitochondrial and cellular toxicity endpoints, cell types used, and their corresponding organs/tissues/system. Each study was assigned to one row in the file and information on whether a positive or negative outcome observed for each endpoint as well as the Q score associated with each study was also included.
The implementation of the AOP framework in RA can bridge the gap between mechanistic toxicological data and regulatory safety assessment for NMs. Ideally, AOPs suitable for RA should undergo a thorough weight-of-evidence evaluation process and be reviewed and endorsed/approved by experts. However, the number of such AOPs is still limited. Among the AOPs identified here that are NM-relevant and cover mitochondrial KEs, the majority of approved AOPs are related to the nervous system, whereas those for the lung, liver, and cardiovascular system are either not included in the OECD work plan or still under development (Tab. 6). These AOPs should be further developed toward OECD approval to increase their regulatory acceptance. The endorsement of NM-relevant AOPs could be facilitated by the discovery of substantial evidence for KERs between MIEs induced by NMs and the KEs in an endorsed AOP.
Funding This work was funded by  EU   H2020  project ( H2020-NMBP-13-2018 RIA ):  RiskGONE (Science-based Risk Governance of Nan-oTechnology ) under grant agreement nº  814425. The work of  Sivakumar Murugadoss  and  Alexandra Schaffert  was funded by the  European Union 's  Horizon 2020 research and innovation program  under grant agreement No. 101037090  (project ALTERNATIVE). The work of  Ivana Vinković Vrček  and  Barbara Pem  was additionally supported by the " Research Cooperability" Program  of the  Croatian Science Foundation  funded by the  European Union  from the  European Social Fund  under the  Operational Programme Efficient Human Resources 2014-2020  (grant  HRZZ-PZS-2019-02-4323 ). The work of  Anita Sosnowska ,  Maciej Stępnik ,  Marvin Martens ,  Egon Willighagen ,  Tomasz Puzyn  and  Maria Dusinska  has been also supported by  EU   H2020  project ( H2020-NMBP-14-2018 RIA ):  NanoSolveIT  ( Innovative Nanoinformatics models  and tools:  towards a Solid, verified and Integrated Approach to Predictive (eco )Toxicology)  under grant agreement nº  814572.
While inhibitor 5 displays effective inhibition, the fate of 5 in the presence of Sulf-2 remains unknown: whether the C(6)O-S bond is hydrolyzed or 5 simply binds to the active site and functions as a competitive inhibitor requires further investigation. A. K. is grateful to the EPSRC and OxStem for financial support. S. E. thanks EPSRC SBM CDT (EP/L015838/1) for a studentship. This work was also supported by the ''Investissements d'avenir'' program Glyco@Alps (ANR-15-IDEX-02) and a grant from the Agence Nationale de la Recherche (ANR-17-CE11-0040). I. B. S. acknowledges integration into the Interdisciplinary Research Institute of Grenoble (IRIG, CEA).
Thus, this paper focuses on the design, the implementation and the test of energy autonomous Sensing Nodes (SN), fully buried in reinforced concrete and part of a Wireless Sensor Network. These are battery-free, wirelessly and remotely powered and controlled, and capable of measuring and wirelessly transmitting relevant data for the Structural Health Monitoring of reinforced concretes. These communicate data over kilometers thanks to the LoRaWAN wireless communication technology and are wirelessly powered over several meters (at least up to 11 meters) in all the directions from a power source respecting the European regulations. By using simultaneously the 868 MHz Industrial, Scientific and Medical (ISM) frequency band for both the wireless communication and the Wireless Power Transfer, the proposed Sensing Nodes meet the Simultaneous Wireless Information and Power Transfer paradigm with a unique antenna.
The power management subsystem is composed of: a harvester (a rectenna, i. e. an antenna and a RF-to-DC rectifier, here connected through a radiofrequency circulator) used to harvest the radiative electromagnetic power generated and transmitted by the Communicating Node(s) and to convert it into DC electrical power; and a Power Management Unit (PMU) used to efficiently recover the power provided by the rectenna, to store it in energy storage buffer (here a supercapacitor), and to power the data management subsystem once enough energy is available. The data management subsystem is composed of a MicroController Unit (MCU) which drives a sensor and a wireless transceiver (here a LoRaWAN one) connected to the same antenna as for the power management subsystem (through the radiofrequency circulator).
On the Sensing Nodes side, the received input signal for the Wireless Power Transfer has a lower power level than the output one used for the data transmission. Thus, the output signal is not altered whatever the waveform of the input signal. Moreover, this behavior is further enhanced by the high isolation of the radiofrequency circulator between the output and input channels. So, there is no interference for the Sensing Nodes. On the Communicating Nodes side, the output signal for the Wireless Power Transfer is considered as noise by the LoRaWAN input frame receiver. There is also no interference thanks to the noise resistance of Chirp Spread Spectrum technique. DOI: 10. 1109/JIOT. 2023. 3321958 IoT-30049-2023 Thus, a new solution and implementation of the Simultaneous Wireless Information and Power Transfer paradigm is provided, without temporal, frequential, or spatial multiplexing, neither power splitting, but with a discrimination/separation through the circulator of the sense of signal flows (data from the transceiver to the antenna and power from the antenna to the rectifier).